Biopharmaceutical Manufacturing as Strategic Infrastructure in the GCC — And Why Opal’s Platform Matters Now For years, the GCC
Monoclonal Antibodies: The Commercial Engine of Modern Biopharma in the GCC Over the past two decades, monoclonal antibodies (mAbs) have
Biopharmaceutical Manufacturing as Strategic Infrastructure in the GCC — And Why Opal’s Platform Matters Now For years, the GCC has
Commercial “go-live” moments in biopharmaceutical manufacturing are often misunderstood. They are frequently framed as commercial launches or revenue milestones, when
For health systems across the Gulf, advanced therapies such as CAR-T have historically been accessed through outbound medical evacuation. Patients
Medical tourism in the Gulf is entering a new phase. The traditional model—patients flying long distances for complex oncology and
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
